Latest News

  • Digital Endpoints: Trends and Opportunities in Drug Development and Beyond

    Diagnostics World | When the Digital Medicine Society (DiMe) launched its Library of Digital Endpoints, a listing of industry-sponsored studies of new medical products or applications that use sensor-derived endpoints, there were a total of 35. Four years later, that same library now includes over 400 unique digital endpoints collected by over 60 sponsors to answer questions about the efficacy of new medical products.

    Jan 23, 2024
  • JP Morgan Healthcare on Acquisitions, AI Advancements, More

    Diagnostics World | At this year’s JP Morgan Healthcare conference, biotech and diagnostic companies and experts provided overviews of 2023 accomplishments and their goals for 2024. We’ve covered presentations by NVIDIA, Regeneron, Illumina, Pacific Biosciences, and Oxford Nanopore in depth. Here we list highlights from Pfizer, Moderna, Eli Lilly, Thermo Fisher, and more.

    Jan 17, 2024
  • Oxford Nanopore at JP Morgan: Native DNA Advantage

    Diagnostics World | CEO Gordan Sanghera gave Oxford Nanopore’s first live presentation at the JP Morgan Healthcare Conference last week. He highlighted his platforms accuracy and the company’s consumable growth.

    Jan 16, 2024
  • PacBio at JP Morgan: Revio, Onso, Three Sequencing Platforms in Development

    Diagnostics World | Christian Henry, President and CEO of Pacific Biosciences, was unabashedly cheerful at the JP Morgan Healthcare Conference on Wednesday afternoon when he gave the updates for PacBio. “2023 absolutely exceeded our expectations,” he said, basking in two platform launches, strong consumable growth, and three new platforms in development.

    Jan 12, 2024
  • Illumina at JP Morgan: Tighter Focus, Consumable Growth, Short Read Market

    Diagnostics World | CEO Jacob Thaysen presented Illumina’s updates yesterday at the JP Morgan Healthcare Conference. 2023 has been an eventful year for the sequencing pioneer with December’s announcement that Illumina would divest GRAIL; Francis deSouza, Illumina’s former CEO, stepping down in June; and $175M in cost cuts over the course of 2023 which included headcount reductions and major real estate changes. Thaysen presented Illumina at a turning point.

    Jan 9, 2024
  • ‘Reverse Metabolomics’ Enables Biological Discoveries From Repository Data

    Diagnostics World | In a turnaround of the usual metabolomics study approach, University of California San Diego scientists are homing in on the microbial-produced molecules that interact with cells and affect human health. A couple million such molecules are likely awaiting discovery in this fashion.

    Jan 9, 2024